The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...
Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach ...
siRNA therapies show promise for treating diseases like cancer and genetic disorders, but their effectiveness depends on proper delivery. A recent study found that the method of mixing siRNA with ...
Pharmaceutical Technology on MSN
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset
As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.
It is the second licensing deal involving siRNA between GSK and a Chinese biotech in the last few months, coming after the UK ...
However, siRNA's therapeutic potential is limited by off-target effects, which occur when the siRNAs interact with non-target mRNA strands. These unintended interactions can lead to harmful ...
Suzhou Ribo Life Science Co., Ltd. ('Ribo', 06938.HK) announced that the Company has entered into a strategic collaboration ...
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced the first subject has been dosed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results